Floatz logo

Parsaclisib

Ann Arbor Stage II Follicular Lymphoma

Innovent Biologics (Suzhou) Co. Ltd.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

209 Active assets in the Ann Arbor Stage II Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

Parsaclisib is also rated in:

marginal zone lymphomaDormant
B
Indicative ·
60 / 100
View asset →
lymphomaDormant
B
Indicative ·
58 / 100
View asset →
cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →